コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 of NMO lesions in mice made neutrophilic by granulocyte colony stimulating factor.
2 duce proinflammatory genes, such as CCL2 and granulocyte colony-stimulating factor.
3 ing recombinant zebrafish erythropoietin and granulocyte colony-stimulating factor.
4 obilization induced by a CXCR4 antagonist or granulocyte colony-stimulating factor.
5 nia in G6PC3 deficiency and responds well to granulocyte colony-stimulating factor.
6 th increased levels of circulating IL-17 and granulocyte colony-stimulating factor.
7 ecreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor.
8 ion and enhanced marrow homing compared with granulocyte colony-stimulating factor.
9 CD34(+) and CD45(+) cells and of circulating granulocyte colony-stimulating factor.
10 nors, and is synergistic in combination with granulocyte-colony stimulating factor.
11 den but was augmented by coadministration of granulocyte-colony stimulating factor.
12 (ethylene glycol) modified recombinant human granulocyte-colony stimulating factor.
13 usion, tumor necrosis factor inhibitors, and granulocyte colony-stimulating factors.
14 3 ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alo
16 in systemic inflammatory markers, including granulocyte colony-stimulating factor (adjusted OR 2.8 [
17 mobilized more CD34 cells in fewer days than granulocyte colony-stimulating factor alone and allowed
18 nd quantitatively more HSPC from the BM than granulocyte colony-stimulating factor alone, including i
20 bute to an infectious phenotype such as anti-granulocyte colony stimulating factor and anti-IFN-alpha
22 the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via
23 n 1beta, monocyte chemotactic protein 1, and granulocyte colony-stimulating factor and decreased leve
24 ssor cells, which release elevated levels of granulocyte colony-stimulating factor and granulocyte ma
25 CCL1, CCL2, CCL3, CCL5), and growth factors (granulocyte colony-stimulating factor and granulocyte-ma
26 Within 4 days, bone marrow cells cultured in granulocyte colony-stimulating factor and granulocyte-ma
27 ficient) mice, they maintained expression of granulocyte colony-stimulating factor and leukemia inhib
28 ine 45 mg/m2 administered every 14 days with granulocyte colony-stimulating factor and quinolone prop
29 tudies the chemokine GRObeta synergizes with granulocyte colony-stimulating factor and when used alon
31 tion prevented CXCL12 induction and improved granulocyte-colony stimulating factor and ischemia-induc
32 e primed macrophages in adulthood and raised granulocyte-colony stimulating factor and neutrophil cou
33 l expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix
34 luid myeloperoxidase, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels
35 d increased BAL fluid IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels
36 1983) or ADE versus fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (F
37 , and etoposide; or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin.
38 select interleukins, growth factors such as granulocyte colony-stimulating factor, and l-ferritin, h
39 reduced concentrations of interleukin-1beta, granulocyte colony-stimulating factor, and matrix metall
40 CCR2 and CX3CR1 up-regulation, whereas CCL1, granulocyte colony-stimulating factor, and MIP1alpha wer
41 h significantly higher IL-1beta, IL-6, IL-8, granulocyte colony-stimulating factor, and monocyte chem
42 , soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.
43 ls produced higher levels of interleukin-10, granulocyte colony-stimulating factor, and transforming
44 icin 120 mg/m(2) and ifosfamide 9 g/m(2) and granulocyte colony-stimulating factor (arm A) or to rece
45 a levels of interleukin-1alpha and -beta and granulocyte-colony stimulating factor as well as increas
46 atory protein 1alpha, interleukin 1beta, and granulocyte colony-stimulating factor, as well as interl
47 on of the knob-domain of Ab-coil with bovine granulocyte colony-stimulating factor (bGCSF) results in
50 uction of IL-6, CXCL8, CCL2, CCL3, CCL5, and granulocyte colony-stimulating factor by IL-1-stimulated
51 locyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, CCL2, and CCL5, w
52 O mice had decreased concentrations of IL-6, granulocyte colony stimulating factor, chemokine CXC lig
53 pheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via aph
54 fts were mobilized with cyclophosphamide and granulocyte colony-stimulating factor, collected by peri
55 sted whether chemotherapy and treatment with granulocyte colony-stimulating factor (CSF) changed the
56 NOS2 up-regulation, whereas neutrophils and granulocyte-colony-stimulating factor (CSF) were promine
57 tely linked to innate immune cell expansion (granulocyte colony-stimulating factor), cytotoxicity (in
58 a monocyte differentiation program in human granulocyte colony-stimulating factor-dependent neutroph
59 ta show that hematopoietic stress, including granulocyte colony-stimulating factor, do not increase t
60 mune illness, and stroke in donors receiving granulocyte colony-stimulating factor during this period
62 d fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks).
63 mly assigned to fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) or to FLAG
64 nsivist-led service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed meli
66 gation of BSA, beta2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three
67 d neutrophil-activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocy
69 to the treatment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administra
70 the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against st
72 phil expansion and migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemok
73 yte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexame
75 sed body weight, and increased production of granulocyte colony-stimulating factor (G-CSF) and IL-1be
76 -response genes in mucosal RNA and increased granulocyte colony-stimulating factor (G-CSF) and IP-10
77 o myeloid lineage specification, we compared granulocyte colony-stimulating factor (G-CSF) and macrop
78 Rgamma) produced severely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nit
79 AE, in response to systemic up-regulation of granulocyte colony-stimulating factor (G-CSF) and the EL
80 stigates the potential protective effects of granulocyte colony-stimulating factor (G-CSF) and underl
81 or neutrophil response despite high doses of granulocyte colony-stimulating factor (G-CSF) are at gre
82 independence 1 (Gfi1) and the growth factor granulocyte colony-stimulating factor (G-CSF) are indivi
83 CAIX is indispensable for the production of granulocyte colony-stimulating factor (G-CSF) by hypoxic
84 phage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) can affect
85 ith the clinically relevant mobilizing agent granulocyte colony-stimulating factor (G-CSF) caused rap
86 ), along with local interleukin (IL)-12, and granulocyte colony-stimulating factor (G-CSF) concentrat
87 , MIP-1beta, and IL-15 and semen eotaxin and granulocyte colony-stimulating factor (G-CSF) concentrat
88 ation of bone marrow-derived stem cells with granulocyte colony-stimulating factor (G-CSF) could prom
89 is was 0.4 x 10(9)/L, and median ANC without granulocyte colony-stimulating factor (G-CSF) during fol
91 Finally, the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced R
93 marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become
97 d the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobiliz
99 ne recommended primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) instead of
102 stem/progenitor cell (HSPC) mobilization by granulocyte colony-stimulating factor (G-CSF) is mediate
105 ocyte chemoattractive protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in
107 od stem cell (PBSC) mobilization response to granulocyte colony-stimulating factor (G-CSF) may identi
110 antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves
111 Investigations in this model revealed that granulocyte colony-stimulating factor (G-CSF) produced b
112 was to describe the effect of antibiotic and granulocyte colony-stimulating factor (G-CSF) prophylaxi
114 who were administered T-BEP received primary granulocyte colony-stimulating factor (G-CSF) prophylaxi
116 1 (LEF-1), which plays a definitive role in granulocyte colony-stimulating factor (G-CSF) receptor-t
117 of-function mutations in CSF3R, encoding the granulocyte colony-stimulating factor (G-CSF) receptor.
118 ) or the combination of GRObeta(Delta4) plus granulocyte colony-stimulating factor (G-CSF) restore ne
120 of VEGF, epidermal growth factor (EGF), and granulocyte colony-stimulating factor (G-CSF) secretion.
121 es the risk of myelotoxicity and may require granulocyte colony-stimulating factor (G-CSF) support.
122 greatest differential was with the cytokine granulocyte colony-stimulating factor (G-CSF) that cause
123 BM) to the blood circulation by the cytokine granulocyte colony-stimulating factor (G-CSF) through co
124 rleukin-17 (IL-17) induced the expression of granulocyte colony-stimulating factor (G-CSF) through nu
125 lls for transplantation, use of the cytokine granulocyte colony-stimulating factor (G-CSF) to mobiliz
126 mononuclear cells (BMMC) and the ability of granulocyte colony-stimulating factor (G-CSF) to mobiliz
127 vances in the therapeutic use of recombinant granulocyte colony-stimulating factor (G-CSF) to promote
128 donors were mobilized and collected without granulocyte colony-stimulating factor (G-CSF) using AMD3
129 ulate MTA1 expression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen
130 erleukin 1 receptor antagonist (IL-1Ra), and granulocyte colony-stimulating factor (G-CSF) were raise
132 ls were randomized to receive plerixafor and granulocyte colony-stimulating factor (G-CSF), agents kn
133 er levels of cytokines/chemokines, including granulocyte colony-stimulating factor (G-CSF), and enhan
134 ony formation, decreased in vivo response to granulocyte colony-stimulating factor (G-CSF), and impai
135 a), tumor necrosis factor alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), and inter
138 lassemic patients mobilized with hydroxyurea+granulocyte colony-stimulating factor (G-CSF), G-CSF, Pl
139 interleukin 1beta (IL-1beta), IL-6, IL-17A, granulocyte colony-stimulating factor (G-CSF), granulocy
141 15, tumor necrosis factor alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), interfero
143 IL-15), IL-18, gamma interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte
144 Tlr4 and Myd88 and are the primary source of granulocyte colony-stimulating factor (G-CSF), the key g
147 ophil count and their priming is mediated by granulocyte colony-stimulating factor (G-CSF), which acc
148 cally, TLR4 and NOD1 synergistically induced granulocyte colony-stimulating factor (G-CSF), which was
149 4+ peripheral-blood stem cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which wer
151 che cells and their role in cyclophosphamide/granulocyte colony-stimulating factor (G-CSF)-induced HS
152 Functional studies demonstrated elevated granulocyte colony-stimulating factor (G-CSF)-induced pr
153 ately 35% at 1 year after transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized
154 nse to damaged cells, promoting an excessive granulocyte colony-stimulating factor (G-CSF)-regulated
155 capitulates a Gfi1 loss-of-function block to granulocyte colony-stimulating factor (G-CSF)-stimulated
156 opulation that appears in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated do
162 MIP-2)/CXCL2, IP-10/CXCL10, MIP-1alpha/CCL3, granulocyte colony-stimulating factor (G-CSF)/CSF3, CXCL
163 increases in IL-1alpha/beta, IL-6/IL-12(p40)/granulocyte colony-stimulating factor (G-CSF)/keratinocy
164 ve mice but can be induced by treatment with granulocyte colony-stimulating factor (G-CSF/Csf3) or by
166 he combination of stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) (SCF+G-CSF
167 he neuroprotective effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem c
170 by a novel mechanism in which tumor-derived granulocyte-colony stimulating factor (G-CSF) directs ex
171 few published cases, there is evidence that granulocyte-colony stimulating factor (G-CSF) in patient
175 ence coverage was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to M
178 of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimulating factor (G-CSF), a dipepti
179 ating levels of neutrophils are regulated by granulocyte-colony stimulating factor (G-CSF), but not i
180 her key inflammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL
181 he metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which exp
182 kaemia (AML) samples, and downregulated upon granulocyte-colony stimulating factor (G-CSF)- mediated
183 ncouraging outcomes after transplantation of granulocyte-colony stimulating factor (G-CSF)- primed un
186 aly in adulthood due to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these eff
187 is, we identify the proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) a
188 -term repopulating capacity as well as hyper granulocyte-colony-stimulating factor (G-CSF)-induced mo
189 ]) and differences (interleukin-6 [IL-6] and granulocyte colony-stimulating factor [G-CSF]) elicited
190 okines (interferon gamma, interleukin 6, and granulocyte colony-stimulating factor [G-CSF]) were high
191 lammatory mediators (including CXCL1, CXCL2, granulocyte colony-stimulating factor [G-CSF], interleuk
192 al use of zebrafish Tpo, erythropoietin, and granulocyte colony stimulating factor (Gcsf) allowed the
193 ignificant controversy surrounds the role of granulocyte colony stimulating factor (GCSF) in levamiso
196 lin (ATG), as well as the mobilization agent granulocyte colony-stimulating factor (GCSF), to reverse
197 (6S,7S,8S)-1a and (6R,7S,8S)-1b inhibited granulocyte colony-stimulating factor (GCSF)-stimulated
199 hropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating factor (GCSFR), and JAK2.
200 nterleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyte colony-stimulating factor given every 21 day
201 erleukin-17, basic fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte macro
202 ulating levels of IL-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macro
203 emonstrate that a post-BMT regimen of either granulocyte-colony stimulating factor, growth hormone, p
206 and exhibited significantly lower levels of granulocyte colony stimulating factor, IL-8, macrophage
207 proinflammatory cytokines, including RANTES, granulocyte colony-stimulating factor, IL-6, IL-1alpha,
208 of machrophage colony stimulating factor and granulocyte colony stimulating factor in splenic macroph
210 erestingly, we also found elevated levels of granulocyte colony-stimulating factor in conditioned med
211 gG deposits and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of
212 CCL2/monocyte chemoattractant protein 1, and granulocyte colony-stimulating factor in lung homogenate
213 al blood stem cells mobilized by AMD3100 and granulocyte colony-stimulating factor in patients demons
214 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pre
215 ed in diabetic mice lacking the receptor for granulocyte colony-stimulating factor in their marrow-de
216 f serum cytokines showed increased levels of granulocyte colony-stimulating factor in transgenic anim
217 r stem cell mobilization in combination with granulocyte-colony stimulating factor in patients with n
220 d that AMD3465, alone or in combination with granulocyte colony-stimulating factor, induced mobilizat
221 mobilized more circulating neutrophils after granulocyte colony-stimulating factor infusion compared
222 sis demonstrated significant upregulation of granulocyte colony-stimulating factor, interferon gamma,
223 e elevated in the posttransplantation phase: granulocyte colony-stimulating factor, interleukin-8, ti
224 eraction chromatography of recombinant human granulocyte colony stimulating factor is demonstrated.
226 A-EX) mice had less IL-6, interleukin 12p40, granulocyte colony-stimulating factor, keratinococyte-de
227 te proinflammatory cytokines (interleukin-6, granulocyte colony-stimulating factor, keratinocyte chem
228 rotein-1, macrophage inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chem
229 rrelated with the production of 5 cytokines (granulocyte colony-stimulating factor, keratinocyte-deri
230 for 5 days on days 10-14; two cycles), with granulocyte-colony stimulating factor (lenograstim) supp
231 he treatment diminished circulating IL-6 and granulocyte colony-stimulating factor levels and limited
232 locyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, macrophage colony
233 ith no prophylactic use of recombinant human granulocyte-colony stimulating factor mandated in this g
234 are (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus
235 X-C motif) receptor 4 antagonist AMD3100 and granulocyte colony-stimulating factor mobilized more CD3
236 topoiesis seen in DC, we analyzed cells from granulocyte colony-stimulating factor mobilized peripher
237 nsplantation (HCT), either marrow (n = 4) or granulocyte-colony stimulating factor mobilized peripher
238 D161(hi) cells from umbilical cord blood and granulocyte colony stimulating factor-mobilized leukaphe
239 e globulin (ATG) followed by the infusion of granulocyte colony-stimulating factor-mobilized grafts.
240 nditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocyt
241 Following the infusion of PMF and normal granulocyte colony-stimulating factor-mobilized peripher
243 tation of primary functional human MEPs from granulocyte colony-stimulating factor-mobilized peripher
244 ct of a set of immune cells contained within granulocyte colony-stimulating factor-mobilized peripher
245 increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripher
246 imulating factor and when used alone or with granulocyte colony-stimulating factor mobilizes more pri
247 er serum levels of interleukin (IL)-6, IL-8, granulocyte colony-stimulating factor, monocyte chemoatt
248 ecreased interferon-inducible protein 10 and granulocyte colony-stimulating factor more than did nore
250 ary vaccine recipients had maximal levels of granulocyte-colony-stimulating factor on days 6-7 after
251 iesis-stimulating agents in combination with granulocyte colony-stimulating factor or all-trans-retin
255 0.002), IL-6 (P = 0.002), IL-8 (P = 0.026), granulocyte colony-stimulating factor (P = 0.002), and m
256 ene glycol) (PEG), such as recombinant human granulocyte-colony stimulating factor (PEGylated rhG-CSF
257 lone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improv
258 fety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive ca
261 both cytokines regulated CXC chemokines and granulocyte colony-stimulating factor production in the
262 tors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor, provided an expla
263 -derived CD34(+) cells mobilized in blood by granulocyte colony-stimulating factor, purified WAT-CD34
265 hosphatase-1 (SHP-1)-dependent inhibition of granulocyte colony-stimulating factor receptor (G-CSFR)
266 companied by mutations in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR)
268 me high frequency recurrent mutations in the granulocyte colony-stimulating factor receptor gene CSF3
269 cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL)
270 of type I and II cytokine receptors, except granulocyte colony-stimulating factor receptor, which su
271 in the secretory pathway and is required for granulocyte colony-stimulating factor receptor-mediated
272 ed high-frequency oncogenic mutations in the granulocyte-colony stimulating factor receptor (CSF3R) i
273 ause the erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor receptors are all
276 ils, increased in WT mice after injection of granulocyte colony-stimulating factor, resulted in incre
280 s Stat3-NF-kappaB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercell
281 ments with primary keratinocytes showed that granulocyte colony-stimulating factor stimulated Ras act
282 3-deficient cells showed hypersensitivity to granulocyte-colony stimulating factor, suggesting enhanc
283 aily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 wee
288 n antibacterial cytokine response comprising granulocyte colony-stimulating factor, tumor necrosis fa
289 d trial, eligible patients were treated with granulocyte colony-stimulating factor, underwent an aphe
290 valis antibodies, but they were defective in granulocyte colony-stimulating factor upregulation.
291 osis, neutrophil count, type of peg-IFN, and granulocyte colony-stimulating factor use, none of these
292 terferon-gamma, tumor necrosis factor-alpha, granulocyte colony-stimulating factor, vascular-endothel
295 d to support erythroid colony formation, and granulocyte colony-stimulating factor was required to su
298 protein levels of tumor necrosis factor and granulocyte colony-stimulating factor were rapidly upreg
299 serum levels of IFN-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly
300 , and inflammatory cytokines (interleukin-8, granulocyte colony-stimulating factor) were elevated in
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。